Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Long-Term Effects of Medical Implants
SJR: 0.332 SNIP: 0.491 CiteScore™: 0.89

ISSN Print: 1050-6934
ISSN Online: 1940-4379

Journal of Long-Term Effects of Medical Implants

DOI: 10.1615/JLongTermEffMedImplants.v10.i12.50
17 pages

Heparin-Coated Stents

John F. Kocsis
Cordis, a Johnson & Johnson Company, 40 Technology Drive, Warren, NJ 07059, USA
Gerard Llanos
Cordis, a Johnson & Johnson Company, 40 Technology Drive, Warren, NJ 07059, USA
Erik Holmer
Carmeda AB, Bjornnasvagen 21, SE-113 47 Stockholm, Sweden

ABSTRACT

Stenting has revolutionized the field of interventional cardiology. However, early studies revealed a high incidence of thrombotic occlusion of the stent and significant bleeding complications resulting from the use of intensive anticoagulation after implantation. One of the strategies used to reduce stent thrombosis and hemorrhagic complications has been to decrease the thrombogenicity of the stent surface. For this purpose, a unique heparin surface patented by Carmeda AB (Stockholm, Sweden)—the Carmeda® BioActive Surface (CBAS)—has been coated onto Cordis® (Johnson & Johnson) stents. Preclinical evaluations of the thromboresistance of heparin-coated stents and clinical studies of heparin-coated stents in a variety of clinical settings are discussed.